917023-06-4

Usage

Uses

Methyl 2-(5-bromopyridin-2-yl)acetate is used as a key intermediate in the synthesis of various compounds for different applications:
Used in Pharmaceutical Industry:
Methyl 2-(5-bromopyridin-2-yl)acetate is used as a building block for the development of new pharmaceuticals, contributing to the creation of innovative drugs with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 2-(5-bromopyridin-2-yl)acetate is utilized as a precursor in the production of agrochemicals, aiding in the development of effective pesticides and other agricultural chemicals to protect crops and enhance yields.

Upstream product

• 192642-83-4 5-(5-bromo-1H-2-pyridinylidene)-2,2-dimethyl-[1,3]dioxane-4',6-dione 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 3430-13-5 5-bromo-2-methylpyridine 
• 79-22-1 methyl chloroformate 
• 2402-97-3 3-bromopyridine N-oxide 
• 145218-19-5 5-bromo-2-(bromomethyl)pyridine 
• 67-56-1 methanol 
• 312325-72-7 2-(5-bromopyridin-2-yl)acetonitrile 
• 192642-85-6 2-(5-bromopyridin-2-yl)acetic acid 
• 766-11-0 5-bromo-2-fluoropyridine 

Relevant academic research and scientific papers

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart ( e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.

Catalyst-Free Annulation of 2-Pyridylacetates and Ynals with Molecular Oxygen: An Access to 3-Acylated Indolizines

A catalyst and additive-free annulation of 2-pyridylacetates and ynals under molecular oxygen was the first developed, affording 3-acylated indolizines in good to excellent yields. Molecular oxygen was used as the source of the carbonyl oxygen atom in indolizines. This approach was compatible with a wide range of functional groups, and especially it has been successfully extended to unsaturated double bonds and triple bonds, which were difficult to prepare by previous methods in a single step.

A One-Pot Sonogashira Coupling and Annulation Reaction: An Efficient Route toward 4 H -Quinolizin-4-ones

An efficient one-pot Sonogashira coupling and annulation reaction affording 4 H -quinolizin-4-ones in moderate to excellent yields is described. A variety of substituted iodoarenes and 2-alkylazaarenes were well tolerated, and especially the unsaturated double and triple bonds were compatible under the standard conditions.

Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)

The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clinical trial candidat

BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE

The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.

RhIII-Catalyzed C-H Activation with Pyridotriazoles: Direct Access to Fluorophores for Metal-Ion Detection

The first C-H bond activation with pyridotriazoles as coupling partners is presented using a RhIII catalyst. The pyridotriazoles can be used as new carbene precursors in C-H activation for direct access to novel fluorescent scaffolds. These tunable fluorophores can be applied for the detection of metal ions.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER

The present invention is directed to a compound of formula I, and processes for the manufacture of said compounds as well as medicaments containing said compound. The compounds according to this invention show anti-proliferative and differentiation-induci

VITAMIN D-LIKE COMPOUND

The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable